Rationale: Dystrophic calcinosis occurs in chronically damaged tissue in patients with complicated autoimmune diseases. The therapeutic options are limited, and the treatment response rate is variable. Here, we describe a rare case of dystrophic calcinosis treated with leflunomide in a patient with overlap syndrome.
Introduction
Dystrophic calcinosis with overlap syndrome is extremely rare in rheumatic diseases. The exact mechanism of calcinosis is still unknown, and no approved effective therapy currently exists. [1] However, in this article, we experienced a rare case of dystrophic calcinosis overlapping with systemic sclerosis (SSc) and rheumatoid arthritis (RA). The patient was treated medically using leflunomide, instead of surgery.
Case report
A 53-year-old woman was admitted to our hospital in December of 2013, with complaints of slow growing mass on her hand with no history of trauma. She had been treated for limited cutaneous SSc since 2008. Based on the 2013 American College of Rheumatology/European League Against Rheumatism (ACR/ EULAR) criteria, a diagnosis of SSc was reconfirmed according to the presence of the following findings: skin thickening of fingers (4 points), Raynaud's phenomenon (3 points), antinuclear antibody 1:640 (nucleolus type; anticentromere and anti-scl70 antibodies: 3 points). She was on calcium channel blockers, proton pump inhibitors, and colchicine. In 2009, she was diagnosed with RA based on the RA 2010 ACR criteria according to the following findings: multiple arthritis with increased rheumatoid factor at 218 U/mL (normal < 18 U/mL) and anticitrullinated protein antibody at 538 IU/mL (normal < 5 IU/mL). In 2011, we diagnosed her with overlap syndrome including RA and SSc. She was treated with methotrexate, hydroxychloroquine, sulfasalazine, and low-dose steroid. In addition to these clinical signs, she could not move her hands due to pain. Her peripheral blood smear showed the following: leukocyte count, 13,200/mm 3 ; hemoglobin level, 10.3 g/dL; and platelet count, 336,000/mm 3 . Her blood chemistry revealed sodium, 142 mM/L; potassium, 3.8 mM/L; chloride, 101 mM/L; calcium, 7.6 mg/dL; phosphorous, 3.6 mg/dL; uric acid, 8.6 mg/ dL; total protein, 6.7 g/dL; albumin, 3.5 g/dL; aspartate aminotransferase, 54 U/L; alanine aminotransferase, 15 U/L; alkaline phosphatase, 154 U/L; total bilirubin, 1.2 mg/dL; prothrombin time, 10.7 seconds; erythrocyte sedimentation rate, 120 mm/h (normal < 30 mm/h); and C-reactive protein, 9.14 mg/dL (normal < 0.05 mg/dL). Her urinalysis results were normal. Viral antibody tests were performed again, revealing HBs Ag (À), HBs Ab (À), HCV Ab (À), and Hba1C of 5.4%. Simple radiography of both hands showed tumoral calcinosis. Bone scan showed active arthritis on both hands (Fig. 1 ). Biopsy and histologic findings were consistent with dystrophic calcinosis and collagen vascular overlap syndrome. Her treatment medication was changed to leflunomide 20 mg/d, methotrexate 15 mg/wk, and prednisolone 10 mg/d. One month after the change in medication, improvement in arthritis was noted in both hands. She was free from hand pain with no changes in the neurological status or recurrence. Twelve months follow-up imaging revealed improved tumoral calcinosis (Fig. 2) . Controlled rheumatoid disease activity has been obtained after using leflunomide, until recently.
Written informed consent was obtained from the patient for the purpose of publication of this case report and any accompanying image. A copy of the patient consent form from the written consent is available for review by the editor of this journal. Because of this, there is no need to conduct special ethic review and the ethical approval is not necessary. 
Discussion
Although dystrophic calcinosis is rare in connective tissue diseases, and the accurate pathogenesis unknown, [1] it is known to occur in tissues that are somehow altered to promote calcification with normal serum levels of calcium and phosphorous as in our present patient. The pathophysiology of dystrophic calcinosis may include chronic tissue inflammation, structural defects, and hypoxemia. [1] Moreover, the calcium and phosphorous can bind to the denatured proteins of the necrotic cells that may act as a core for dystrophic calcinosis in location of trauma or inflammation. [2] In this case, repeated inflammatory chain reactions may play an important role in the development of calcinosis in hands, where synovitis often occurs in patients with refractory collagen vascular diseases, especially in those with RA. Dystrophic calcinosis is often presented as a developing mass in the soft tissues around major joints, such as elbows and knees, and it often has a hard nodule in sacral area that can result in secondary local inflammation, muscle atrophy, or joint contracture. The pleomorphic calcium phosphate crystals are restricted to soft tissue, usually extensor surfaces of joints with bone destruction and the growth of pleomorphic calcium phosphate crystals may also lead to mass effects on the neurovascular structures. However, sometimes calcinosis can remain asymptomatic, with radiographs showing calcific deposits. [3, 4] There is no standard treatment for dystrophic calcinosis, although warfarin, colchicine, probenecid, bisphosphonate, diltiazem, minocycline, aluminum hydroxide, and salicylate have been used. However, none of the drugs convincingly prevents or reduces dystrophic calcinosis with great success. [5] [6] [7] Some reports suggested that surgical resection could be beneficial for large lesions and should be considered when dystrophic calcinosis cause severe local pain or diminishes the quality of life. [8] [9] [10] However, in our case, the patient was treated with leflunomide, an immunomodulatory drug hypothesized to affect the pathogenesis of RA by invoking a response from activated T lymphocytes. [11] The primary action of leflunomide was selective inhibition of dihydroorotate dehydrogenase, a key enzyme involved in pyrimidine synthesis, thus inhibiting de novo pyrimidine synthesis. [12] Whether leflunomide had a local direct effect on calcified nodule or a systemic indirect effect on RA inflammation is unknown; however, we hypothesize that the treatment of RA inflammation resolves dystrophic calcinosis. In some reports, the prognosis of dystrophic calcinosis may improve in patients who have undergone an early initiated aggressive therapy for underlying disease. [13, 14] Moreover, in the present case, an early aggressive therapy was initiated from the beginning of RA and the drug change was changed to leflunomide during the course of the disease.
In some respects, the use of leflunomide in our case may have accidentally treated dystrophic calcinosis. However, we inferred that the treatment of the underlying disease was the best clinical management of dystrophic calcinosis, and the use of leflunomide might be a pharmacological treatment option for treating dystrophic calcinosis in RA patients.
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